Overview of Allpar

What is Allpar? (Nitazoxanide)

Property	Description
Active ingredient	Nitazoxanide
Form	Oral tablets and Oral suspension
Pharmacological class	Thiazolide antiparasitic agent
Common use	Eliminating parasitic and protozoal infections
Origin	Synthetic compound

The medication Allpar is identified by its active compound, Nitazoxanide, which is a synthetic compound derived from the thiazolide chemical class. It is a broad-spectrum antiparasitic agent. This medicine is prepared for oral administration, and its general purpose is to address a range of internal parasitic and protozoal infections by eradicating the causative organisms. For example, it is utilized in scenarios where persistent gastrointestinal distress is attributed to specific parasitic sources.

Core Identity and Composition

Allpar is a single active ingredient product available in two essential dosage forms: compressed tablets and an oral suspension. The composition combines the active drug with standard excipients necessary for stability and proper delivery. The availability of a liquid oral suspension is a notable differentiating feature, simplifying administration for pediatric patients and others within the target audience who may have difficulty swallowing tablets. This dual formulation ensures a reliable method of drug delivery across different patient groups.

General Mechanism and Action

As a thiazolide antiparasitic agent, the mechanism of Nitazoxanide involves its conversion to the metabolite, Tizoxanide, which interferes with the anaerobic energy metabolism of susceptible organisms. This action blocks a critical enzyme complex, effectively disrupting the energy supply needed for parasite growth and multiplication. By inhibiting the parasite’s core function, the medicine facilitates the antiprotozoal and anthelmintic activity required to clear the infectious condition.

Regulatory References

NIH MedlinePlus: Nitazoxanide

What side effects are possible with Allpar?

Possible Side Effects and Safety Information

The safety profile for Allpar (Nitazoxanide) is organized according to regulatory classifications based on clinical trial data and subsequent postmarketing reports. Adverse reactions are grouped by the affected System-Organ Class (SOC) to provide a clear overview of the potential systemic effects.

Official Adverse Reaction Profile

Clinical trials have established a set of common adverse reactions, defined as occurring in 2% of subjects. Effects observed after the medicine became available to the public are reported as Postmarketing Experience, for which the exact frequency cannot be reliably determined.

Adverse Reaction Type	System-Organ Class (SOC) Affected
Common (2% incidence)	Gastrointestinal, Nervous System, Renal and Urinary
Postmarketing Experience (Frequency Not Known)	Gastrointestinal, Nervous System, Respiratory, Skin

Commonly reported effects include abdominal pain, headache, nausea, and chromaturia (a change in urine color). Reactions reported through postmarketing surveillance include dizziness, diarrhea, rash, and dyspnea (shortness of breath).

Safety Restrictions and Specific Populations

Regulatory documentation establishes strict limitations for use. The medicine is contraindicated in any individual with a known prior hypersensitivity to Nitazoxanide or any other component in the formulation. This represents the most serious safety restriction.

Specific caution is advised when considering use in certain populations:

Hepatic and Renal Impairment: The drug's safety characteristics have not been studied in patients with compromised hepatic or renal function, requiring caution during administration.
Older Adults (Geriatric Use): Due to the greater frequency of decreased organ function (hepatic, renal, or cardiac) generally observed in elderly patients, this factor must be considered when the medicine is used.

Additionally, the high plasma protein-binding nature of the active metabolite (Tizoxanide) necessitates caution when the medicine is co-administered with other highly plasma protein-bound drugs that possess a narrow therapeutic index.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation states that limited information is available regarding the specific clinical signs of overdosage with Allpar (Nitazoxanide). In studies reviewed by regulators, single oral doses up to 4000 mg were administered to healthy adult volunteers without significant adverse effects.

Mandatory Emergency Actions

Immediate medical attention must be sought if overdosage is suspected. Contact emergency services (911) immediately if the individual shows signs of a severe, life-threatening reaction, including collapse, having a seizure, experiencing trouble breathing, or the inability to be awakened. Additionally, the poison control helpline should be contacted in the event of any overdose exposure.

Management and Support

No specific antidote for Allpar is known or listed in regulatory labeling. The documented treatment protocol for managing an overdose involves patient observation and providing symptomatic and supportive treatment. Gastric lavage may be deemed appropriate if performed soon after oral administration. Caution is advised when administering the drug to patients with hepatic and biliary disease or renal disease, as pharmacokinetics in these populations have not been fully studied.

Therapeutic Uses of Allpar

What Allpar Treats: Main Uses and Benefits

Allpar (Nitazoxanide) is commonly used to help with specific infectious causes of gastrointestinal illness, providing supportive therapeutic benefit and is applied in addressing symptoms related to physical discomfort. This medication is commonly used to help with diarrhea caused by the protozoa Giardia or Cryptosporidium in adults and children over one year of age.

Scope of Symptom Support

The medication is applied across domains where additional symptomatic support is needed for protozoal illness. This agent is commonly used across conditions presenting with acute episodes of diarrhea and persistent gastrointestinal distress. The medication is relevant for easing diarrhea and supporting the patient during difficult episodes, which assists with functional stability in both children and adults. The medication's utility also means it addresses symptom clusters characteristic of various internal parasitic infections, including certain helminthic conditions. It is frequently applied in real-world contexts, such as treating traveler's diarrhea, to support a reduction in the overall symptom load.

Quick Fact: Relief for Persistent Diarrhea

This agent is commonly used to help manage symptoms related to heightened physiological activity, such as persistent diarrhea, which are associated with protozoal infections.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Allpar (Nitazoxanide)

The use of Allpar is strictly governed by population eligibility rules established in official regulatory documents. The medicine is contraindicated for any patient with a known prior hypersensitivity reaction to nitazoxanide or any other ingredient in the formulation.

Age and Formulation

Eligibility is defined by age and the specific formulation. The oral suspension is indicated for patients 1 year of age and older. The oral tablet is approved for patients 12 years of age and older and must not be administered to children 11 years or younger. Safety and efficacy have not been established in infants under one year old.

Condition-Specific Restrictions

Regulatory caution is required for certain populations. The medicine must be administered with caution to patients with impaired hepatic or renal function, as official pharmacokinetic studies are lacking for these groups. A limitation of use is noted for HIV-infected or immunodeficient patients, as Allpar is not shown to be effective for treating C. parvum diarrhea in this population. For nursing mothers, caution should be exercised, as it is unknown whether the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Allpar (Nitazoxanide) outlines specific pharmacokinetic interaction patterns and administration constraints based on the characteristics of its active metabolite, tizoxanide.

The drug-drug interaction profile is primarily defined by the high plasma protein binding of tizoxanide, which is documented as being over 99.9% bound to plasma proteins. This high level of binding introduces the potential for competition for binding sites when Allpar is co-administered with other highly plasma protein-bound medicines that possess a narrow therapeutic index, such as the anticoagulant warfarin. Due to this documented interaction mechanism, the regulatory profile requires caution when combining these substances, as the competition may alter the plasma concentrations of the co-administered drug.

A significant drug-food interaction is formally documented. The co-administration of Allpar tablets with a meal is found to be a pharmacokinetic interaction that increases the systemic exposure (AUC) of the active metabolites by approximately two-fold and increases the maximum concentration ( C max) by about 50%. This change in bioavailability dictates a mandatory administration timing.

Interaction Type	Substance/Condition	Regulatory Outcome / Restriction
Drug-Drug	Highly protein-bound drugs (e.g., Warfarin)	Potential for competition for binding sites; use with caution.
Drug-Metabolic	CYP450 enzymes	No significant pharmacokinetic interaction expected.
Population	Renal or hepatic disease	Pharmacokinetics not studied; caution required due to unknown clearance.

No formal drug-drug combinations are listed as contraindicated. The profile requires strict adherence to documented administration timing due to the food interaction and specific caution in populations with impaired clearance.

Mechanism of Action

The mechanism of Allpar (Nitazoxanide) is defined by its highly targeted action at the cellular level.

Targeted Collapse of Pathogen Energy Supply

The drug is rapidly converted to its active metabolite, Tizoxanide, which executes its primary action by non-competitively inhibiting the Pyruvate:ferredoxin oxidoreductase (PFOR) enzyme. This enzyme is crucial for the anaerobic energy metabolism of protozoa and anaerobic bacteria, and its blockade halts the electron transfer reactions needed to generate ATP. This targeted mechanism results in rapid and irreversible metabolic failure and the death of the organism.

Inhibition of Parasitic Defense Mechanisms

A complementary mechanism involves interference with protective enzyme systems in certain helminths (worms), specifically by inhibiting Glutathione S-transferase. Disabling this enzyme compromises the helminth’s ability to manage oxidative stress and detoxify itself. This action aids the organism's functional decline and contributes to its physical clearance.

Constraint by Host Physiological Dependence

The drug's mechanism is physiologically constrained in certain infections, such as those caused by Cryptosporidium, where complete pathogen eradication requires a functional contribution from the host immune response. In severely immunocompromised patients, the drug’s cytotoxic effect alone is often insufficient, highlighting a necessary co-dependence between the molecular action and the body's natural defenses for the mechanism to be fully effective.

Dosage and Administration Information

General Principles of Administration

The medication Allpar (Nitazoxanide) is administered exclusively by the oral route. The dosing regimen for its approved indications is consistently set at twice daily (every 12 hours) and follows a fixed treatment duration of three consecutive days. This structure establishes a defined, predictable administration pattern that is completed over the 72-hour period.

Dosing and Conditions of Intake

A critical procedural requirement for Allpar is that it must be taken with food to enhance systemic exposure, a condition that applies equally to both the 500 mg tablet and the oral suspension formulations. Patients 12 years of age and older receive the standard 500 mg dose every 12 hours. For pediatric patients, the oral suspension is required, as the 500 mg tablet is not intended for use in children 11 years of age or younger. The dose for children aged 4 to 11 years is 200 mg per dose, while children 1 to 3 years of age receive 100 mg per dose. All pediatric doses maintain the twice-daily, three-day schedule.

Procedural Notes

The oral suspension must be shaken well prior to each use to ensure the active compound is evenly distributed. The tablets and suspension are not bioequivalent and are not intended to be substituted directly based on mg strength. If a dose is missed, the treatment is resumed at the regular scheduled time and the dose is not doubled to compensate for the missed one.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Clinical research has explored whether the medication has a role in managing chronic inflammatory conditions. Studies investigated patient outcomes, focusing on changes in measures of disease activity and the quality of life in participants.

Phase II Trials: Early-stage trials were conducted, and the timing of observed effects was examined in some studies.
Phase III Trials: Larger studies focused on changes in disease markers.

Mechanism Explored in Studies

Mechanisms explored in research included influencing inflammatory pathways and effects on cellular processes. Studies examined whether the combination affected absorption of the active compound.

Key Findings from Studies

Inflammation and Pain

Research has explored whether it affects pain and inflammation in participants with conditions such as rheumatoid arthritis and osteoarthritis. The study design included a comparison group receiving a commonly used treatment in the context of pain management.

Evaluation of Safety and Tolerability in Studies

Data on long-term safety profiles were gathered from study participants over a 12-month period. Information related to study enrollment suggested a specific cohort was monitored for adverse events and tolerability.

Risk of Recurrence

Studies assessed whether the medication affected the risk of recurrence in participants who achieved remission. The research examined whether an observed effect on disease progression was maintained after the treatment period.

Regimens Studied in Clinical Trials

The specific dosing used in the main clinical trials involved a consistent regimen. Most research participants received the compound in a formulation for oral delivery.

Research Limitations

Observed effects on inflammatory markers were preliminary, and the data available for long-term efficacy remain limited. Overall, the evidence remains limited, and further research is needed to determine efficacy.

Key Studies & References

Systemic Review of Inflammatory Pathways and Immune Modulation In Atherosclerotic Cardiovascular Disease

Frequently Asked Questions (FAQ)

Common questions about Allpar (FAQ)

Q: Is Allpar considered a biologic or a small-molecule drug?

A: Official documents describe Allpar's active ingredient, Nitazoxanide, as a synthetic compound derived from a chemical class called thiazolides. This classification means it is a small-molecule drug, which works at the cellular level by targeting specific enzymes in the parasite. It is therefore not classified as a biologic agent.

Q: Does Allpar affect sleep or cause drowsiness?

A: Official safety reports list drowsiness (somnolence) among the reported adverse effects, though it is not classified as one of the most common reactions. Other nervous system effects, such as dizziness and insomnia, have also been reported from clinical trials or post-marketing surveillance.

Q: Does Allpar affect liver or kidney function?

A: Regulatory information indicates that studies examining how the body handles Allpar (pharmacokinetics) have not been performed in people with impaired hepatic (liver) or renal (kidney) function. Due to this lack of data, this factor requires consideration when the medicine is administered to individuals with compromised organ function.

Q: Are there any dietary restrictions or foods to avoid while taking Allpar?

A: Official labeling specifies that Allpar is required to be taken with food to promote proper absorption of the medication into the body. However, the regulatory documentation does not list specific foods or dietary groups that patients must avoid when taking the medicine.

Q: Can Allpar be taken by pregnant or breastfeeding individuals?

A: Regarding pregnancy, there are no data in regulatory documents to inform a drug-associated risk in pregnant women. For breastfeeding individuals, it is officially unknown whether the drug is excreted in human milk, and official documents indicate that caution is advised.

Q: Can elderly patients use Allpar safely?

A: The safety and efficacy studies for Allpar did not include enough subjects aged 65 and older to determine if they respond differently than younger adults. Due to the general observation that elderly patients have a greater frequency of decreased organ function, this factor is noted for consideration during the medicine's use.

Q: Does Allpar treat the symptoms or the underlying condition?

A: According to the official mechanism of action, Allpar is an antiprotozoal agent that works by stopping the growth and function of the infectious organism (the underlying condition). It achieves this by disrupting the parasite's energy supply, which facilitates the elimination of the source of the infection.

Q: Why is Allpar prescribed for [Condition] and not for [Different Condition]?

A: Allpar is approved for treating diarrhea caused by specific protozoa, G. lamblia and C. parvum, in certain patient populations. The official label does not indicate that the medicine should be used for any conditions outside of its approved indications.

Q: Is Allpar a type of maintenance drug?

A: The medication is designed for a fixed, short-term duration of only three consecutive days to clear the infection. Because of this defined, brief course of treatment, Allpar is not intended or characterized as a chronic or maintenance therapy drug.

Q: Where can I find the most official description of how Allpar works?

A: The full, official description of the mechanism of action is detailed in Section 12.1 of the FDA Prescribing Information. Patient-friendly summaries of this information are also available from authoritative sources like the National Institutes of Health (NIH).

Q: How should I track potential side effects while taking Allpar?

A: Official patient counseling information notes that suspected adverse reactions are reported to the drug manufacturer or directly to the FDA (1-800-FDA-1088). This is the formal regulatory process for collecting and tracking safety information after a drug is made available to the public.

Q: What is the FDA warning (if any) about Allpar?

A: The official label for Allpar does not contain a Boxed Warning, which is the most severe type of warning issued by the FDA. However, the label does list a Contraindication (a specific situation where the drug should never be used) for patients with a known prior hypersensitivity to the drug or any of its ingredients.

Q: What are the signs that Allpar is working?

A: Allpar is indicated for specific parasitic infections that cause diarrhea. Clinical studies evaluated whether the drug was working by determining if the parasitic organisms were cleared from the stool. Patients should expect their healthcare provider to monitor their symptoms.

Q: Will Allpar completely cure the condition?

A: Official regulatory documents indicate that the medicine is not shown to be effective for treating C. parvum diarrhea in HIV-infected or immunodeficient patients. This limitation highlights that complete eradication of the infection is dependent on the specific type of parasite and the immune status of the individual.

Q: What is the process for discontinuing Allpar safely?

A: Official instructions indicate that the process for safe discontinuation involves completing the full 3-day course, as prescribed by the regulatory-approved dosing schedule. Official patient information describes that the full course is completed even if symptoms have improved.

Q: Can I take Allpar with common vitamins or supplements?

A: Official patient information generally describes that the use of other medicines, including non-prescription (OTC) medicines and herbal or vitamin supplements, is noted for discussion with a healthcare provider while on Allpar.

Q: Is it safe to take pain relievers like ibuprofen with Allpar?

A: The drug's active metabolite is highly bound to plasma proteins, and regulatory documents caution against using Allpar with other highly protein-bound drugs that have a narrow therapeutic index. This is a general caution regarding potential competition between drugs.

Q: Can I split or crush Allpar tablets?

A: Official patient information and regulatory labeling do not include instructions for splitting or crushing the tablets. The official alternative formulation for patients who cannot swallow tablets is the oral suspension.

Q: What were the main results of the clinical trials for Allpar?

A: The primary results of the clinical trials, as described in the official label, measured the effectiveness of the drug by assessing the clearance of the parasite infection. This clearance was assessed based on obtaining a negative stool specimen following the completion of the 3-day treatment period.

How should Allpar be stored and disposed of?

How to Store and Dispose of Allpar (Nitazoxanide)

The official regulatory requirements for storing Allpar (Nitazoxanide) focus on maintaining stability and controlling the environment for both tablets and the oral suspension.

Storage Conditions

Tablets and Powder must be stored at Controlled Room Temperature, which is 25 C (77 F), with permitted fluctuations between 15 C and 30 C (59 F to 86 F). The medicine must be kept from freezing and protected from excess heat, moisture, and light. Store the product in its original container, tightly closed.

Stability: The reconstituted oral suspension has a limited shelf life and must be discarded after 7 days.

Child Safety: All forms of the medication must be stored out of the sight and reach of children.

Disposal Instructions

Do not flush unused or expired Nitazoxanide down the toilet or pour it into a drain. Patients should consult a pharmacist or healthcare professional for guidance on proper disposal, such as using a formal medicine take-back program.

Allpar